Extract Chronic lung allograft dysfunction (CLAD) remains the primary cause of long-term death or graft-failure after lung transplantation. The ScanCLAD trial demonstrated that tacrolimus-based immunosuppression significantly reduced CLAD incidence compared to ciclosporin (13% versus 39% at 3 years). However, CLAD phenotyping was not part of the original protocol. We report the first comprehensive phenotype analysis from a prospective randomized controlled trial in lung transplantation, employing a structured consensus process to classify CLAD phenotypes and assess their stability over time.
Magnusson et al. (Fri,) studied this question.